EUCTR2004-005028-42-GB进行中（未招募）不适用
A prospective, multi-centre, phase III-b study of TachoSil in paediatric patients scheduled for resection of the liver with or without segmental liver transplantation - TachoSil paediatric liver study
ycomed Danmark ApS0 个研究点目标入组 40 人开始时间: 2006年1月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Infomed consent obtained from the parents(s)/legal gurdian.
- •Minor or moderate haemorrhage from the cut surface after liver resection with or without segmental liver transplantation and after primary haemostatic treatment. Age above 4 weeks and below 6 years.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Congenital coagulation disorders. Serious surgical complications. Hypersensitivity to the active substances or to any of the excipients.
研究者
相似试验
进行中（未招募）
不适用
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyAdult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVAMedDRA version: 7.0Level: PTClassification code 10037153EUCTR2004-001236-23-ATSerono International S.A.1,500
进行中（未招募）
不适用
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyAdult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVAMedDRA version: 7.0Level: PTClassification code 10037153EUCTR2004-001236-23-DKSerono International S.A.1,500
进行中（未招募）
不适用
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyEUCTR2004-001236-23-FISerono International S.A.1,500
进行中（未招募）
1 期
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyAdult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVAMedDRA version: 7.0Level: PTClassification code 10037153EUCTR2004-001236-23-ESSerono International S.A.1,500
进行中（未招募）
1 期
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVA. - efalizumab physician experience studyAdult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including cyclosporin, methotrexate and PUVAMedDRA version: 7.0Level: PTClassification code 10037153EUCTR2004-001236-23-SKSerono International S.A.1,500